Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy, radiotherapy, and Apatinib in extensive-stage small cell lung cancer
ChiCTR2500109886Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and Rivoceranib in small cell lung cancer (SCLC), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: 12-month progression-free survival rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500109886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109886.